These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30369730)

  • 21. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD; Dinh BC
    J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).
    Pession A; Melchionda F; Castellini C
    Biologics; 2008 Mar; 2(1):129-41. PubMed ID: 19707436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
    McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
    Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.
    Alakel N; Middeke JM; Schetelig J; Bornhäuser M
    Onco Targets Ther; 2017; 10():597-605. PubMed ID: 28203093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
    Patel KS; Lau JE; Zembillas AS; Gallagher EM
    J Oncol Pharm Pract; 2017 Jul; 23(5):333-337. PubMed ID: 27084514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2010 Jun; (6):CD006945. PubMed ID: 20556770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy.
    Dinnel J; Moore BL; Skiver BM; Bose P
    Core Evid; 2015; 10():23-38. PubMed ID: 25610345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.
    Hummel M; Reiter S; Adam K; Hehlmann R; Buchheidt D
    Eur J Haematol; 2008 Apr; 80(4):331-6. PubMed ID: 18081720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of single-dose rasburicase in an obese female.
    Arnold TM; Reuter JP; Delman BS; Shanholtz CB
    Ann Pharmacother; 2004 Sep; 38(9):1428-31. PubMed ID: 15292497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
    Abousaud MI; Rush MC; Rockey M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1165-1171. PubMed ID: 32727320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome.
    Majumdar S; Sharma N; Sengar M; Thorat J; Nayak L; Bonda A; Bagal B; Rajendra A; Sethi A; Jain H
    Leuk Lymphoma; 2023 Mar; 64(3):628-638. PubMed ID: 36891578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
    Bessmertny O; Robitaille LM; Cairo MS
    Curr Pharm Des; 2005; 11(32):4177-85. PubMed ID: 16375739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose rasburicase in hematologic malignancies.
    Jayabose S; Kumar V; Dhanabalan R; Rajan P; Rathnam K; Viswanathan TK
    Indian J Pediatr; 2015 May; 82(5):458-61. PubMed ID: 25338496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective review of rasburicase utilization in pediatric and adult patients across a large health system.
    Kamel A; Sanders M; Dyk H; Hamilton T
    J Oncol Pharm Pract; 2024 May; ():10781552241253214. PubMed ID: 38794946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
    Jeha S; Pui CH
    Contrib Nephrol; 2005; 147():69-79. PubMed ID: 15604607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.
    Gopakumar KG; Thankamony P; Seetharam S; P K
    Pediatr Hematol Oncol; 2017 May; 34(4):206-211. PubMed ID: 28872997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
    Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
    Bertrand Y; Mechinaud F; Brethon B; Mialou V; Auvrignon A; Nelken B; Notz-Carrère A; Plantaz D; Patte C; Urbieta M; Baruchel A; Leverger G;
    J Pediatr Hematol Oncol; 2008 Apr; 30(4):267-71. PubMed ID: 18391694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.